Cost-effectiveness of integrated disease management for high risk, exacerbation prone, patients with chronic obstructive pulmonary disease in a primary care setting

Table 2 Trial-based results (i.e., 1 year simulation starting at age 68)

Probabilistic Results	Life Years	Costs	QALYs	ICUR	ICER	Net Benefit
Usual Care Group	0.97	$921	0.686
IDM Group	0.97	$654	0.788
Incremental	0.00	− $267*	0.102*	Dominant	Dominant	$ 5,360

Dominance/ Dominant = a treatment that is less costly and results in improved health outcomes; ICER = Incremental Cost Effectiveness Ratio; ICUR = Incremental Cost Utility Ratio; Net Benefit = Differential in QALY * Willingness to Pay per QALY—Differential in Cost; QALYs = Incremental Quality Adjusted Life Years (IDM vs. UC)
^*Statistically significant to p < 0.01

ISSN: 1478-7547